pan). According to generally used guidelines (5), we diagnosed the subjects based on each ABI value as follows: Յ0.90, low ABI (diagnosed as PAD); 0.91-1.30, normal ABI; Ͼ1.30, noncompressive. We thereby excluded the subjects with ABI Ͼ1.30 (n ϭ 27).
We performed a statistical analysis in 2,261 type 2 diabetic subjects: 35.5% male, mean Ϯ SD 60.6 Ϯ 10.0 years of age, 6.0 Ϯ 6.4 years duration of diabetes, 50.0% cigarette smokers, 24.0 Ϯ 3.4 kg/m 2 BMI, 6.9 Ϯ 1.3% A1C, 60.9% hypertensive (systolic blood pressure Ն140 mmHg, diastolic blood pressure Ն90 mmHg, or having been treated for hypertension), and 62.2% dyslipidemic (serum total cholesterol Ն220 mg/dl, serum triglycerides Ն150 mg/dl, HDL cholesterol Ͻ40 mg/dl, or having been treated for dyslipidemia). Low ABI was identified for 51 subjects, and the prevalence of low ABI was significantly higher in subjects with TT genotype than CC or CT genotype (7.2 vs. 2.0%; P ϭ 0.0008). There were no differences among the genotypes for the other parameters including sex, age, duration of diabetes, history of smoking, BMI, A1C, presence of hypertension, and presence of dyslipidemia. Furthermore, a multiple logistic regression analysis revealed that the TT genotype was a risk factor for low ABI independently of traditional risk factors (odds ratio 3.78 [95% CI 1.61-8.89]; P ϭ 0.0023).
Because a negative ABI cannot completely rule out PAD, further studies are required to reach a conclusion. This study, however, suggests that the connexin37 C1019T polymorphism is associated with PAD in Japanese type 2 diabetic patients. 
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